Grant: Fellowship - Priority Announcement: Pandemic Preparedness and Health Emergencies
University of Calgary
$135,000.00
Immunotherapy through microbiota modification to prevent hospital-acquired infections
FY 2023-24
Summary
The human gut is home to trillions of bacteria. Normally, these bacteria and their associated functions, termed the microbiome, maintain our immune systems development and function. Disruptions to the microbiome (dysbiosis) has been linked to disease and immune dysfunction. Critically ill patients in the intensive care unit (ICU) experience extremely high rates of deadly hospital-acquired infections. Critically ill patients also experience immune suppression and dysfunction, which has been found to be driven by dysbiosis. Specifically, overgrowth of a family of gut bacteria called Enterobacteriaceae has been found to drive immune dysfunction and lead to increased susceptibility to nosocomial infections and death in critically ill patients. The Enterobacteriaceae family includes known pathogenic bacteria such as E. coli. It is currently unclear how exactly Enterobacteriaceae expansion leads to immune dysfunction and the inability for patients to fight infections. Establishing this link will facilitate the development of microbiome-targeted therapies to restore immune function and prevent nosocomial infections in critical illness. Using the world-class UCalgary International Microbiome Centre facilities, we will decipher the cellular and molecular mechanisms by which ICU-acquired Enterobacteriaceae drive immune dysfunction in vivo, and design engineered microbiome therapies to reverse this pathological microbe-immune interaction. Precisely defined colonization experiments in germ-free mice, coupled with cutting-edge methods to dissect the in vivo immune response will be used to define the mechanisms of immune dysfunction driven by gut Enterobacteriaceae. Next, use this mechanistic knowledge and apply it to a novel "immunotherapy through microbiome modification" by treating mice with defined microbial therapies (next-generation probiotics) aimed at displacing Enterobacteriaceae and reversing its impact on immunity and host defense against infection.
Department
Program
Fellowship - Priority Announcement: Pandemic Preparedness and Health Emergencies
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
497760
Name
Cho Nicole
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Immunotherapy through microbiota modification to prevent hospital-acquired infections
Programtype2
Fellowship Programs
Orgnameinp2
University of Calgary
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
Fellowship - Priority Announcement: Pandemic Preparedness and Health Emergencies
Keyworddelim
Critical Illness; Flow Cytometry; Germ Free; Gut Microbiota; Immunology; Intravital Microscopy; Mass Spectrometry; Nosocomial Infection; Precision Medicine; Probiotic
Abstract
The human gut is home to trillions of bacteria. Normally, these bacteria and their associated functions, termed the microbiome, maintain our immune systems development and function. Disruptions to the microbiome (dysbiosis) has been linked to disease and immune dysfunction. Critically ill patients in the intensive care unit (ICU) experience extremely high rates of deadly hospital-acquired infections. Critically ill patients also experience immune suppression and dysfunction, which has been found to be driven by dysbiosis. Specifically, overgrowth of a family of gut bacteria called Enterobacteriaceae has been found to drive immune dysfunction and lead to increased susceptibility to nosocomial infections and death in critically ill patients. The Enterobacteriaceae family includes known pathogenic bacteria such as E. coli. It is currently unclear how exactly Enterobacteriaceae expansion leads to immune dysfunction and the inability for patients to fight infections. Establishing this link will facilitate the development of microbiome-targeted therapies to restore immune function and prevent nosocomial infections in critical illness. Using the world-class UCalgary International Microbiome Centre facilities, we will decipher the cellular and molecular mechanisms by which ICU-acquired Enterobacteriaceae drive immune dysfunction in vivo, and design engineered microbiome therapies to reverse this pathological microbe-immune interaction. Precisely defined colonization experiments in germ-free mice, coupled with cutting-edge methods to dissect the in vivo immune response will be used to define the mechanisms of immune dysfunction driven by gut Enterobacteriaceae. Next, use this mechanistic knowledge and apply it to a novel "immunotherapy through microbiome modification" by treating mice with defined microbial therapies (next-generation probiotics) aimed at displacing Enterobacteriaceae and reversing its impact on immunity and host defense against infection.
Competitiondate
202310
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Cho, Nicole
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~